CSU – Talk Bio

Actionable Insights Powered by AI

Third Harmonic Bio to Liquidate, Selling Key Urticaria Drug Asset THB335

1 week ago talkbio0Tagged biopharma exit strategy, Chronic Spontaneous Urticaria, clinical-stage, CSU, drug sales, Inhibitor, KIT, Kit device, shareholder, THB335, Third Harmonic Bio liquidation, value maximization

Third Harmonic Bio liquidation , THB335 drug sale , chronic spontaneous urticaria (CSU) , KIT inhibitor , biopharma exit strategy , clinical-stage biotech , shareholder value maximization

AAD25: Ahead of CSU filing, Novartis’ BTK inhibitor shows sleep benefits

1 month ago talkbio0Tagged Chronic Spontaneous Urticaria, CSU, Novartis, remibrutinib, Sleep

Chronic Spontaneous Urticaria, remibrutinib, Sleep, CSU, Novartis